Drugs / SRD-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06224660 | Oct 2024 → Oct 2027 expected | familial dilated cardiomyopathy | Sardocor Corp. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04703842 | Sep 2021 → Dec 2025 overdue | systolic heart failure | Sardocor Corp. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224660 ↗ |
| Known as | AAV1/SERCA2a | “A Phase 1/2 Trial of the Safety and Efficacy of SRD-001 (AAV1/SERCA2a) in Subjects With Heart Failure With Reduced Ejection Fraction” NCT04703842 ↗ |
| Action | Restore | “targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis” NCT04703842 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus serotype 1 (AAV1) vector expressing the transgene” NCT04703842 ↗ |
| Route | Other | “one-time intracoronary infusion” NCT04703842 ↗ |